Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3632 results
Audentes, Genethon to develop treatment for x-linked myotubular myopathy
06 February 2014 | By PBR Staff Writer
US-based biotechnology firm Audentes Therapeutics and Genethon, a non-profit organization dedicated to the research and development of biotherapies for orphan genetic diseases, have entered into an agreement to develop AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM).
Drug Research > Drug Discovery & Development > News
AV Therapeutics, DavosPharma to produce chemotherapeutic drug Capridine
06 February 2014 | By PBR Staff Writer
US-based developer of cancer therapeutics and vaccines AV Therapeutics has entered into an agreement with DavosPharma to assist in the Good Manufacturing Practices (GMP) synthesis of its lead drug candidate Capridine.
Drug Research > Drug Discovery & Development > News
Regulus renews strategic alliance with Sanofi to focus on orphan disease and oncology targets
06 February 2014
Regulus Therapeutics has renewed its strategic alliance with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets.
Drug Research > Drug Discovery & Development > News
Merck partners with Amgen, Incyte and Pfizer on new anti-cancer regimens with MK-3475
06 February 2014 | By PBR Staff Writer
Merck through its subsidiaries has signed three separate clinical collaboration agreements with Amgen, Incyte and Pfizer to assess new combination regimens with its investigational anti-PD-1 immunotherapy, MK-3475.
Drug Research > Drug Discovery & Development > News
Hawaii Biotech awarded anthrax anti-toxin grant by NIAID
05 February 2014
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech a grant to continue the development of anthrax anti-toxin drugs.
Drug Research > Drug Discovery & Development > News
Bayer, DKFZ extend existing alliance to develop new cancer therapies
05 February 2014 | By PBR Staff Writer
Bayer HealthCare and the German Cancer Research Center (DKFZ) have extended their strategic research alliance for another five years to develop new cancer therapies.
Drug Research > Drug Discovery & Development > News
Ablynx signs cancer immunotherapy collaboration, licensing agreement with Merck
04 February 2014 | By PBR Staff Writer
Belgian biopharmaceutical firm Ablynx has entered into a second research collaboration and licensing agreement with a subsidiary of Merck.
Drug Research > Drug Discovery & Development > News
Selcia, University of Edinburgh enter GBP2.5m project for new fatal disease drug
04 February 2014 | By PBR Staff Writer
UK-based life sciences contract research organization (CRO) Selcia and scientists from the University of Edinburgh have jointly launched a GBP2.5m project to develop new drugs for the treatment of sleeping sickness.
Drug Research > Drug Discovery & Development > News
EdisonPharma enters into drug development agreement with Dainippon Sumitomo
03 February 2014 | By PBR Staff Writer
US-based Edison Pharmaceuticals has entered into agreement with Japanese pharmaceutical firm Dainippon Sumitomo Pharma (DSP) worth $4.295bn for the development of new drugs targeting cellular energy metabolism.
Drug Research > Drug Discovery & Development > News
Regado Biosciences announces $20m private placement
03 February 2014
Regado Biosciences, a biopharmaceutical company focused on the late-stage clinical development of its actively controllable antithrombotic drug system, REG1, has entered into a definitive agreement to sell $20m of its common stock in a private placement to new and existing investors.
Drug Research > Drug Discovery & Development > News
FOB Synthesis enters into antibiotic development agreement with AstraZeneca
28 January 2014 | By PBR Staff Writer
US-based FOB Synthesis and AstraZeneca have entered into a research and development option and license agreement for the development of a novel antibiotic for the treatment of drug-resistant bacterial infections.
Drug Research > Drug Discovery & Development > News
NIBIO, Aeras, Create Vaccine sign agreement to develop new TB vaccines
28 January 2014 | By PBR Staff Writer
The National Institute of Biomedical Innovation of Japan (NIBIO), Aeras, and Create Vaccine have signed a collaboration agreement for the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO’s human parainfluenza type‐2 (rhPIV2) vector technology.
Drug Research > Drug Discovery & Development > News
Teva and Active Biotech remain committed for development of Nerventra for multiple sclerosis
27 January 2014
Teva Pharmaceutical Industries and Active Biotech have announced that both companies remain committed to the Nerventra (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Drug Research > Drug Discovery & Development > News
Celsion initiates development program for glioblastoma brain tumors with thermodox and HIFU
23 January 2014
Celsion, an oncology drug development company, has announced that the company is formalizing a program to pursue the development of ThermoDox to investigate applications for treating brain cancer tumors, notably Glioblastoma Multiforme or GBM.
Drug Research > Drug Discovery & Development > News
Actavis confirms court upholds Lo Loestrin Fe patent
21 January 2014
Actavis has confirmed that the US District Court for the District of New Jersey found US Patent No 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals abbreviated new drug applications (ANDAs) for generic versions of Actavis' Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).
Drug Research > Drug Discovery & Development > News
61-75 of 3632 results